<DOC>
	<DOCNO>NCT00819741</DOCNO>
	<brief_summary>This trial conduct Asia . The aim clinical trial investigate blood sugar lower effect repaglinide plus metformin initial treatment compare repaglinide alone Chinese subject type 2 diabetes HbA1c ( glycosylated haemoglobin A1c ) 8.5 % never take oral sugar-lowering drug . The associated unfavourable event include low blood sugar episode two treatment also compare .</brief_summary>
	<brief_title>Comparison Blood Sugar Lowering Effect Between Repaglinide Plus Metformin Repaglinide Alone Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed type 2 diabetes Never take oral antidiabetic drug HbA1c great 8.5 % BMI ( Body Mass Index ) less equal 35 kg/m^2 Known suspect allergy repaglinide , metformin , excipients medication Taken investigational drug another clinical trial within 4 week prior trial Impaired liver function , define ASAT ( aspartate aminotransferase ) ALAT ( alanine aminotransferase ) equal great 2 time upper normal limit Have clinically significant , active disease gastrointestinal , pulmonary , neurological , renal , genitourinary , haematological system Severe uncontrolled untreated hypertension ( sit diastolic blood pressure ( BP ) equal great 100 mmHg systolic BP equal great 180 mmHg ) Impaired renal function Acute chronic acidosis plan radiographic material contain iodine Have clinically significant , active cardiovascular disease , decompensated heart failure Treatment systemic corticosteroid within past two month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>